Imanova creates its first imaging biomarker for CNS research

Researchers at Imanova have developed a promising new imaging biomarker, 11C-IMA-107, which is the first radioligand labelled with carbon-11 reported for the in vivo visualisation of phosphodiesterase 10A (PDE10A) in humans.

Since its discovery in 1999, PDE10A has been a target of increasing interest from academic research groups and pharmaceutical companies. It has emerged as a particularly interesting target for CNS disorders.

The enzyme breaks down cyclic AMP and cyclic GMP and is selectively present in the striatum, a brain region involved in the transmission of dopamine. This neurotransmitter plays a crucial role in modifying behaviour in response to rewarding or aversive stimuli and plays an important role in motor coordination, such that PDE10A inhibition is thought to be an important target in human CNS disorders where dopamine levels are elevated (as in schizophrenia) or decreased (as in Parkinson's disease).

Imanova researchers demonstrated that 11C-IMA-107 is a promising radioligand for the in vivo quantification of PDE10A in the brain by positron emission tomography and that the radioligand could provide information to further elucidate the PDE10A function, characterise PDE10A expression in disease populations, and also help understanding pharmacological endpoints and therefore accelerate drug development.

The biomarker is available for use now, please contact us for more information.